ACHN reports net loss of $5.6M for first-quarter 2010: MicroStockProfit.com

May 13 2010

MicroStockProfit.com announces an investment report featuring Achillion Pharmaceuticals Inc. (Nasdaq:ACHN).  The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ACHN

Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.  Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections.  As of December 31, 2008, ACHN focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C.

Message Board Search for ACHN: http://www.boardcentral.com/boards/ACHN

In the report, the analyst notes:

"ACHN, a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, recently reported financial results for the three months ended March 31, 2010.  For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009.  Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.  

"ACHN sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas.  The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity.  In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results."